Hagop Kantarjian
MD
Chairman, Department of Leukemia
👥Biography 个人简介
Hagop Kantarjian developed the hyper-CVAD regimen that became a widely adopted standard for adult ALL. He has led numerous landmark trials in ALL, CML, and AML spanning several decades. His contributions to the development of imatinib in CML indirectly transformed ALL treatment approaches through identification of actionable tyrosine kinase targets. He is among the most cited hematologic oncologists worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Hagop Kantarjian 的研究动态
Follow Hagop Kantarjian's research updates
留下邮箱，当我们发布与 Hagop Kantarjian（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment